Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 53, 2018 - Issue 1
Submit an article Journal homepage
842
Views
18
CrossRef citations to date
0
Altmetric
Original Article

PRO-C3: a new and more precise collagen marker for liver fibrosis in patients with chronic hepatitis C

Janne Fuglsang HansenDepartment of Infectious Diseases, Odense University Hospital, Odense, Denmark; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-8039-0699View further author information
ORCID Icon,
Mette Juul NielsenNordic Bioscience A/S, Herlev, Denmark; ORCID Iconhttp://orcid.org/0000-0002-4448-8955View further author information
ORCID Icon,
Kristina NyströmDepartment of Infectious Diseases/Virology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, SwedenView further author information
,
Diana Julie LeemingNordic Bioscience A/S, Herlev, Denmark; View further author information
,
Martin LaggingDepartment of Infectious Diseases/Virology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, SwedenORCID Iconhttp://orcid.org/0000-0002-7995-3626View further author information
ORCID Icon,
Gunnar NorkransDepartment of Infectious Diseases/Virology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, SwedenView further author information
,
Peer Brehm ChristensenDepartment of Infectious Diseases, Odense University Hospital, Odense, Denmark; View further author information
&
Morten KarsdalNordic Bioscience A/S, Herlev, Denmark; View further author information
 show all
Pages 83-87 | Received 02 Aug 2017, Accepted 27 Sep 2017, Published online: 25 Oct 2017

References

  • Muhlberger N, Schwarzer R, Lettmeier B, et al. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health. 2009;9:34.
  • EASL. EASL recommendations on treatment of hepatitis C 2016. [Internet]; 2016. Available from: http://www.easl.eu/research/our-contributions/clinical-practice-guidelines/detail/easl-recommendations-on-treatment-of-hepatitis-c-2016.
  • Rousselet MC, Michalak S, Dupre F, et al. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology. 2005;41:257–264.
  • Pang JX, Pradhan F, Zimmer S, et al. The feasibility and reliability of transient elastography using Fibroscan(R): a practice audit of 2335 examinations. Can J Gastroenterol Hepatol. 2014;28:143–149.
  • Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518–526.
  • Islam S, Antonsson L, Westin J, et al. Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers. Scand J Gastroenterol. 2005;40:867–872.
  • Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317–1325.
  • WHO guidelines for the screening, care and treatment of persons with chronic hepatitis C infection. [Internet]; 2016. Available from: http://www.who.int/hepatitis/publications/hepatitis-c-guidelines-2016/en/.
  • Papastergiou V, Tsochatzis E, Burroughs AK. Non-invasive assessment of liver fibrosis. Ann Gastroenterol. 2012;25:218–231.
  • Karsdal MA, Krarup H, Sand JM, et al. Review article: the efficacy of biomarkers in chronic fibroproliferative diseases – early diagnosis and prognosis, with liver fibrosis as an exemplar. Aliment Pharmacol Ther. 2014;40:233–249.
  • Nielsen MJ, Nedergaard AF, Sun S, et al. The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters. Am J Transl Res. 2013;5:303–315.
  • Nielsen MJ, Kazankov K, Leeming DJ, et al. Markers of collagen remodeling detect clinically significant fibrosis in chronic hepatitis C patients. PLoS One. 2015;10:e0137302.
  • Jansen C, Leeming DJ, Mandorfer M, et al. PRO-C3-levels in patients with HIV/HCV-co-infection reflect fibrosis stage and degree of portal hypertension. PLoS One. 2014;9:e108544.
  • Leeming DJ, Byrjalsen I, Jimenez W, et al. Protein fingerprinting of the extracellular matrix remodelling in a rat model of liver fibrosis – a serological evaluation. Liver Int. 2013;33:439–447.
  • Lagging M, Langeland N, Pedersen C, et al. Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology. 2008;47:1837–1845.
  • DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837–845.
  • Thandassery RB, Al Kaabi S, Soofi ME, et al. Mean platelet volume, red cell distribution width to platelet count ratio, globulin platelet index, and 16 other indirect noninvasive fibrosis scores: how much do routine blood tests tell about liver fibrosis in chronic hepatitis C? J Clin Gastroenterol. 2016;50:518–523.
  • Ozel BD, Poyrazoglu OK, Karaman A, et al. The PAPAS index: a novel index for the prediction of hepatitis C-related fibrosis. Eur J Gastroenterol Hepatol. 2015;27:895–900.
  • Stibbe KJ, Verveer C, Francke J, et al. Comparison of non-invasive assessment to diagnose liver fibrosis in chronic hepatitis B and C patients. Scand J Gastroenterol. 2011;46:962–972.
  • Bashour FN, Teran JC, Mullen KD. Prevalence of peripheral blood cytopenias (hypersplenism) in patients with nonalcoholic chronic liver disease. Am J Gastroenterol. 2000;95:2936–2939.
  • Wright M, Goldin R, Fabre A, et al. Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: a cross sectional and longitudinal study. Gut. 2003;52:574–579.
  • Hourigan LF, Macdonald GA, Purdie D, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology. 1999;29:1215–1219.
  • Chin JL, Pavlides M, Moolla A, et al. Non-invasive markers of liver fibrosis: adjuncts or alternatives to liver biopsy? Front Pharmacol. 2016;7:159.
  • Nielsen MJ, Veidal SS, Karsdal MA, et al. Plasma Pro-C3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C. Liver Int. 2015;35:429–437.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.